Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on July 25, 2022, regarding events reported on July 27, 2022. The filing discloses a significant change in executive leadership, specifically the appointment of a new President and Chief Executive Officer (CEO) and the transition of the interim CEO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: Not less than $480,000 annually for the new CEO.
- Cash Bonus: Target of 75% of base salary based on performance.
- Equity Grant: 2,200,000 stock options at an exercise price of $0.79 per share.
- Severance: 12 months of base salary (increasing to 18 months if termination occurs within 12 months of a change in control).
Material Changes
The primary material change is the appointment of Paul Sekhri as President and CEO, effective August 1, 2022. Concurrently, Richard S. Nelson will cease serving as Interim CEO but will remain on the Board of Directors and as Executive Vice President. Mr. Sekhri brings approximately 30 years of healthcare experience, including previous CEO roles at eGenesis, Lycera Corp., and Cerimon Pharmaceuticals.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingencies relate to the new CEO's employment agreement:
- Vesting Schedule: 25% of options vest on the first anniversary; the remaining 75% vest quarterly over three years, subject to acceleration based on performance metrics.
- Termination Provisions: Specific severance packages apply for termination without "cause" or resignation for "good reason," including COBRA coverage and pro-rata option vesting.
- Restrictive Covenants: The agreement includes two-year post-employment non-compete and non-solicit provisions.
Investor Verification Checklist
- Verify the full terms of the Sekhri Employment Agreement (Exhibit 10.1) and Inducement Award Agreement (Exhibit 10.2) for specific performance metrics tied to option acceleration.
- Confirm the impact of the 2,200,000 option grant on existing shareholder dilution.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership transition.
- Monitor future filings for the formal resignation of Richard S. Nelson from the Interim CEO role effective August 1, 2022.